» Articles » PMID: 39483921

Cell Populations in Human Breast Cancers Are Molecularly and Biologically Distinct with Age

Overview
Journal Res Sq
Date 2024 Nov 1
PMID 39483921
Authors
Affiliations
Soon will be listed here.
Abstract

Aging is associated with increased breast cancer risk and outcomes are worse for the oldest and youngest patients, regardless of subtype. It is not known how cells in the breast tumor microenvironment are impacted by age and how they might contribute to age-related disease pathology. Here, we discover age-associated differences in cell states and interactions in human estrogen receptor-positive (ER+) and triple-negative breast cancers (TNBC) using new computational analyses of existing single-cell gene expression data. Age-specific program enrichment (ASPEN) analysis reveals age-related changes, including increased tumor cell epithelial-mesenchymal transition, cancer-associated fibroblast inflammatory responses, and T cell stress responses and apoptosis in TNBC. ER+ breast cancer is dominated by increased cancer cell estrogen receptor 1 ( and luminal cell activity, reduced immune cell metabolism, and decreased vascular and extracellular matrix (ECM) remodeling with age. Cell interactome analysis reveals candidate signaling pathways that drive many of these cell states. This work lays a foundation for discovery of age-adapted therapeutic interventions for breast cancer.

References
1.
Dai D, Zhong Y, Wang Z, Yousafzai N, Jin H, Wang X . The prognostic impact of age in different molecular subtypes of breast cancer: a population-based study. PeerJ. 2019; 7:e7252. PMC: 6612417. DOI: 10.7717/peerj.7252. View

2.
Hugh J, Haddon L, Githaka J . DREAM On, DREAM Off: A Review of the Estrogen Paradox in Luminal A Breast Cancers. Biomedicines. 2024; 12(6). PMC: 11201522. DOI: 10.3390/biomedicines12061300. View

3.
Mayerhofer C, Sedrak M, Hopkins J, Li T, Tayob N, Faggen M . Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy. J Natl Cancer Inst. 2023; 115(8):981-988. PMC: 10407695. DOI: 10.1093/jnci/djad065. View

4.
Charan M, Das S, Mishra S, Chatterjee N, Varikuti S, Kaul K . Macrophage migration inhibitory factor inhibition as a novel therapeutic approach against triple-negative breast cancer. Cell Death Dis. 2020; 11(9):774. PMC: 7498597. DOI: 10.1038/s41419-020-02992-y. View

5.
Redig A, McAllister S . Breast cancer as a systemic disease: a view of metastasis. J Intern Med. 2013; 274(2):113-26. PMC: 3711134. DOI: 10.1111/joim.12084. View